持续深耕东南亚市场｜海南中和药业2026 CPHI SEA 圆满收官

Continuing to Deepen Presence in Southeast Asia | Hainan Zhonghe Pharmaceutical Successfully Concludes 2026 CPHI SEA

2026年7月8日-10日，CPHI SEA 东南亚制药展于泰国曼谷诗丽吉王后国家会议中心（QSNCC）顺利举办。作为东南亚极具影响力的全产业链医药行业盛会，展会汇聚全球医药企业与专业采购商，是打通东盟医药供应链、拓展东南亚市场的重要商贸平台。我司携多款自研多肽原料药及制剂产品参展，顺利完成本次海外参展行程。

From July 8 to 10, 2026, CPHI South East Asia was successfully held at Queen Sirikit National Convention Center (QSNCC) in Bangkok, Thailand. As a leading full-industry-chain pharmaceutical exhibition across Southeast Asia, it connects global pharmaceutical manufacturers and professional buyers, serving as a key platform to expand the ASEAN pharmaceutical market. Our company showcased a variety of self-developed peptide APIs and finished dosage forms, completing this overseas exhibition smoothly.

本次展会到访展商主要为东盟及周边国家医药分销商与制药企业采购负责人，中和药业国际销售及国际注册团队全程对接客户，开展一对一深度洽谈，细致推介我们的多肽原料药与制剂产品。公司产品布局代谢慢病、肝病抗病毒、心血管抗血栓、胃肠疾病、妇产科及辅助生殖等核心治疗领域，充分匹配东南亚地区市场需求及制剂合规化生产要求。

Visitors to our booth mainly consisted of pharmaceutical distributors and purchasing managers from pharmaceutical manufacturers of ASEAN and neighbouring countries. Our sales and Regulatory Affairs (RA) team engaged in one-on-one in-depth discussions with clients and gave detailed introductions to our peptide APIs and finished dosage forms products. Our product portfolio covers core therapeutic fields including chronic metabolic diseases, anti-hepatitis-B therapy, cardiovascular anti-thrombosis, gastrointestinal illnesses, obstetrics and gynecology and assisted-reproduction, which well adapts to the market needs and requirements for compliant pharmaceutical production across Southeast Asia.

合规性与 GMP 体系是东南亚药企最核心的关注点。基于海南中和药业完备的PIC/sGMP合规资质，我方团队围绕全流程质量管理体系、洁净生产设施、可追溯质检流程及国际合规资质进行讲解，充分展现稳定的品质管控能力，消除客户合作顾虑，达成多项初步合作意向。

GMP compliance and quality management systems are the top priorities for local pharmaceutical partners. Based on Hainan Zhonghe Pharma's complete PIC/S GMP compliance qualifications, our team introduced our full GMP quality control system, clean production workshops, traceable inspection procedures and international compliance certifications, demonstrating consistent quality management capacity, resolving clients’ concerns and reaching several preliminary cooperation intentions.

本次参展为我司深耕东盟市场、提升多肽制剂及原料药品牌影响力奠定良好基础。未来我们将持续坚守 GMP 合规生产标准，优化产品品质，稳步拓展东南亚及全球医药市场，深化长期战略合作。

This exhibition has laid a solid foundation for us to further develop the ASEAN market and strengthen our brand influence in the peptide FDF and API industry. We will continue to follow GMP standards strictly, upgrade product quality, expand our global footprint and build long-term strategic partnerships.